Clioquinol promotes cancer cell toxicity through tumor necrosis factor α release from macrophages

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 360-367

  Du, Tai ^a,b   Filiz, Gulay ^a,b   Caragounis, Aphrodite ^a,b   Crouch, Peter J ^a,b   White, Anthony R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLIOQUINOL; COPPER; NEUTRALIZING ANTIBODY; PROTEASOME; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CLIOQUINOL; COPPER; CYTOKINES; HELA CELLS; HUMANS; MACROPHAGES; MICE; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349020313     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130377     Document Type: Article

References (38)

1. Bala S and Failla ML (1992) Copper deficiency reversibly impairs DNA synthesis in activated T lymphocytes by limiting interleukin 2 activity. Proc Natl Acad Sci U S A 89:6794-6797.
2. Bar-Or D, Thomas GW, Yukl RL, Rael LT, Shimonkevitz RP, Curtis CG, and Winkler JV (2003) Copper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses. Shock 20:154-158.
3. Benvenisti-Zarom L, Chen J, and Regan RF (2005) The oxidative neurotoxicity of clioquinol. Neuropharmacology 49:687-694.
4. Brem S (1999) Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6:436-458.
5. Brewer GJ (2001) Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 226:665-673.
6. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al. (2000) Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6:1-10.
7. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, and Dou QP (2007) Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 67:1636-1644.
8. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, and Kim Y (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
9. Cuderi P (1990) Differential effects of copper and zinc on human peripheral blood monocyte cytokine secretion. Cell Immunol 126:391-405.
10. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, and Dou QP (2005) Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 7:R897.
11. Daniel KG, Gupta P, Harbach RH, Guida WC, and Dou QP (2004) Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 67:1139-1151.
12. Ding WQ, Liu B, Vaught JL, Yamauchi H, and Lind SE (2005) Anticancer activity of the antibiotic clioquinol. Cancer Res 65:3389-3395.
13. Di Vaira M, Bazzicalupi C, Orioli P, Messori L, Bruni B, and Zatta P (2004) Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem 43:3795-3797.
14. Habib FK, Dembinski TC, and Stitch SR (1980) The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta 104:329-335.
15. Huang YL, Sheu JY, and Lin TH (1999) Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem 32:131-136.
16. Ju KD, Yu JH, Kim H, and Kim KH (2006) Role of mitogen-activated protein kinases, NFkappaB, and AP-1 on cerulein-induced IL-8 expression in pancreatic acinar cells. Ann N Y Acad Sci 1090:368-374.
17. Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, Brewer GJ, and Merajver SD (2002) Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4:164-170.
18. Lovejoy DB and Richardson DR (2003) Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 10:1035-1049.
19. Masuda T, Hida H, Kanda Y, Aihara N, Ohta K, Yamada K, and Nishino H (2007) Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat. J Neurosci Res 85:213-222.
20. Mocellin S, Pilati P, and Nitti D (2007) Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr Pharm Des 13:53.
21. Nguyen T, Hamby A, and Massa SM (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102:11840-11845.
22. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, et al. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854-4859.
23. Qiao J, Kang JH, Cree J, Evers BM, and Chung DH (2007) Ets1 transcription factor mediates gastrin-releasing peptide-induced IL-8 regulation in neuroblastoma cells. Neoplasia 9:184-191.
24. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, and Merajver SD (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9:1666-1672.
25. Rice TM, Clarke RW, Godleski JJ, Al-Mutairi E, Jiang NF, Hauser R, and Paulauskis JD (2001) Differential ability of transition metals to induce pulmonary inflammation. Toxicol Appl Pharmacol 177:46-53.
26. Richards DA (1971) Prophylactic value of clioquinol against travellers' diarrhoea. Lancet 1:44-45.
27. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685-1691.
28. Schmalz G, Schuster U, and Schweikl H (1998) Influence of metals on IL-6 release in vitro. Biomaterials 19:1689-1694.
29. Sherman MP, Aeberhard EE, Wong VZ, Griscavage JM, and Ignarro LJ (1993) Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages. Biochem Biophys Res Commun 191:1301-1308.
30. Sidoti-de Fraisse C, Rincheval V, Risler Y, Mignotte B, and Vayssiere J-L (1998) TNFα activates at least two apoptotic signaling cascades. Oncogene 17:1639-1651.
31. Theophanides T and Anastassopoulou J (2002) Copper and carcinogenesis. Crit Rev Oncol Hematol 42:57-62.
32. Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, and Multhaup G (2004) Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 279:51958-51964.
33. Wataha JC, Ratanasathien S, Hanks CT, and Sun Z (1996) In vitro IL-1 beta and TNF-alpha release from THP-1 monocytes in response to metal ions. Dent Mater 12:322.
34. White AR, Barnham KJ, Huang X, Volitakis I, Beyreuther K, Masters CL, Cherny RA, Bush AI, and Cappai R (2004) Iron inhibits neurotoxicity induced by trace copper and biological reductants. J Biol Inorg Chem 9:269-280.
35. White AR, Bush AI, Beyreuther K, Masters CL, and Cappai R (1999) Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. J Neurochem 72:2092-2098.
36. White AR and Cappai R (2003) Neurotoxicity from glutathione depletion is dependent on extracellular trace copper. J Neurosci Res 71:889-897.
37. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, et al. (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281:17670-17680.
38. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, and Oreland L (2000) Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 173:40-44.